Unlike the Janus kinase (JAK) inhibitor baricitinib, which is associated with an increased risk of venous thromboembolism (VTE) at high doses, no increased risk of VTE has been found in patients with rheumatoid arthritis (RA) using the JAK inhibitor tofacitinib compared with those using TNF inhibitors. In a cohort of 50,865 patients with RA in the USA, the occurrence of VTE was <1 per 100 patients, and although the number of reported VTEs was numerically higher in patients using tofacitinib than in those using TNF inhibitors, this difference was not statistically significant (P = 0.13–0.70).
References
Original article
Desai, R. J. et al. Comparative risk of venous thromboembolism with tofacitinib versus tumor necrosis factor inhibitors: a cohort study of rheumatoid arthritis patients. Arthritis Rheumatol. https://doi.org/10.1002/art.40798 (2018)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Collison, J. No increased risk of VTE with tofacitinib. Nat Rev Rheumatol 15, 64 (2019). https://doi.org/10.1038/s41584-019-0162-5
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41584-019-0162-5
